Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2020
Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes
10 March 2020 - The terminology used to describe community participation in health technology assessment is contested and frequently confusing. ...
Posted by Michael Wonder on 04 Feb 2020
Broader types of data to be used in development of NICE guidance
4 February 2020 - An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact ...
Posted by Michael Wonder on 02 Feb 2020
ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework
31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...
Posted by Michael Wonder on 17 Jan 2020
Use of patient preference studies in HTA decision making: a NICE perspective
16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee ...
Posted by Michael Wonder on 15 Jan 2020
Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations
14 January 2020 - HTA recommendations vary widely throughout Europe, even for the same medicine. ...
Posted by Michael Wonder on 14 Jan 2020
FDA approves drugs faster than ever but relies on weaker evidence, researchers find
14 January 2020 - The FDA has gotten faster at approving new prescription drugs over the past four decades, but ...
Posted by Michael Wonder on 09 Jan 2020
Should access to life saving medicines be determined by economic evaluations?
9 January 2020 - Time is the most precious commodity all of us have. ...
Posted by Michael Wonder on 05 Jan 2020
Adding patient reported outcomes to Medicare’s oncology value-based payment model
2 January 2020 - On 1 November 2019, the Centers for Medicare & Medicaid Services Innovation Center released details of a ...
Posted by Michael Wonder on 19 Dec 2019
Request for information on lamotrigine brand change
9 December 2019 - The request, dated 15 November 2019, asked for all and any advice or information or guidance that ...
Posted by Michael Wonder on 11 Dec 2019
Expanding use of multi-criteria decision analysis for health technology assessment
11 December 2019 - As America’s health care system continues to evolve, it is critical that our perception of care ...
Posted by Michael Wonder on 03 Dec 2019
The use of risk-sharing contracts in health care: theoretical and empirical assessments
3 December 2019 - The aim of this review is to provide a summary of the literature on risk-sharing agreements, including ...
Posted by Michael Wonder on 03 Dec 2019
Could or should we use MCDA in the French HTA process?
3 December 2019 - Over the last decade, an increasing literature has been highlighting the benefits of introducing multi-criteria decision analysis ...
Posted by Michael Wonder on 25 Nov 2019
ICER opens nominations for new members of its voting panels
25 November 2019 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 07 Nov 2019
Little consistency in evidence cited by commercial plans for specialty drug coverage
5 November 2019 - Recently published research indicates wide variation in the evidence that US commercial health plans reported reviewing ...